Mouse VE-Cadherin Alexa Fluor® 350-conjugated Antibody Summary
Asp46-Gln592 (Gly67 del, Ile69Asp, Lys70Gln)
Accession # 2208309A
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
The cadherin (Ca++-dependent adherence) superfamily is a large group of membrane-associated glycoproteins that engage in homotypic, calcium-dependent, cell-cell adhesion events. The superfamily can be divided into at least five major subfamilies based on molecule gene structure, and/or extracellular (EC) and intracellular domains (1-4). Subfamilies include classical/type I, atypical/type II, and desmosomal-related cadherins (1-3). VE-Cadherin (vascular endothelial cadherin; also cadherin-5 and CD144) is a 125 kDa atypical/type II subfamily cadherin. Its subfamily classification is based principally on its genomic structure, as its physical structure is notably divergent from other type II subfamily members (2, 3). Mouse VE-Cadherin is synthesized as a 784 amino acid (aa) type I transmembrane (TM) preproprotein that contains a 24 aa signal peptide, a 21 aa prosequence, a 554 aa extracellular region (ECR), a 21 aa TM segment, and a 164 aa cytoplasmic domain (5, 6). The ECR contains five Ca++-binding cadherin domains that are approximately 105 aa in length. Cadherin domains are comprised of two beta ‑sheets that are oriented like bread in a sandwich. Although complex, the N-terminal cadherin domain mediates trans interactions, while the internal domains contribute to cis multimerizations (7). Mouse VE-Cadherin ECR is 92%, 77%, and 73% aa identical to rat, human and porcine VE-Cadherin ECR, respectively. VE-Cadherin is involved in the maintenance of endothelial permeability. In this regard, VE-Cadherin does not initiate new blood vessel formation; it maintains it once formed. Thus, when VE‑Cadherin is downregulated, cells part and permeability increases (8). Notably, VEGF is known to promote vascular leakage, and apparently does so by inducing a beta ‑arrestin-dependent endocytosis of VE-Cadherin (9). Part of this effect may be mediated by VE‑Cadherin itself which is reported to increase the membrane half-life of VEGF R2 (10). VE-Cadherin acts homotypically at sites of zonula adherens. On each expressing cell, it is proposed that VE-Cadherin first forms a trimer, which then dimerizes with a trimeric counterpart in-trans. Alternatively, two cis-dimers could act in-trans to generate homotypic binding (11). In addition to cell adhesion, VE‑Cadherin also is reported to mediate TGF-beta receptor assembly. When clustered, VE‑Cadherin enhances T beta RII/T beta RI assembly into an active receptor complex on endothelial cells (12). VE-Cadherin is expressed on endothelial cells, trophoblast cells, endothelial progenitor cells and embryonic hematopoietic cells (5, 8, 13, 14).
- Patel, S.D. et al. (2007) Curr. Opin. Struct. Biol. 13:690.
- Vestweber, D. (2008) Arterioscler. Thromb. Vasc. Biol. 28:223.
- Vincent, P.A. et al. (2004) Am. J. Physiol. Cell. Physiol. 286:C987.
- Cavallaro, U. et al. (2006) Exp. Cell Res. 312:659.
- Breier, G. et al. (1996) Blood 87:630.
- Huber, P. et al. (1996) Genomics 32:21.
- Pokutta, S. and W.I. Weis (2007) Annu. Rev. Cell Dev. Biol. 23:237.
- Crosby, C.V. et al. (2005) Blood 105:2771.
- Gavard, J. and J.S. Gutkind (2006) Nat. Cell Biol. 8:1223.
- Calera, M.R. et al. (2004) Exp. Cell Res. 300:248.
- Hewat, E.A. et al. (2007) J. Mol. Biol. 365:744.
- Rudini, N. et al. (2008) EMBO J. 27:993.
- Kogata, N. et al. (2006) Circ. Res. 98:897.
- Ema, M. et al. (2006) Blood 108:4018.
Product Specific Notices
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Mouse VE-Cadherin Alexa Fluor® 350-conjugated Antibody
There are currently no reviews for this product. Be the first to review Mouse VE-Cadherin Alexa Fluor® 350-conjugated Antibody and earn rewards!
Have you used Mouse VE-Cadherin Alexa Fluor® 350-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image